CJC-1295 is a synthetic growth hormone-releasing hormone (GHRH) analog widely evaluated in preclinical models for its extended half-life and sustained stimulation of the somatotropic axis. This guide details supplier quality criteria, structural mechanisms, handling protocols, and analytical verification methods for laboratory researchers looking to buy CJC-1295.
CJC-1295 is a synthetic growth hormone-releasing hormone (GHRH) analog widely evaluated in preclinical models for its extended half-life and sustained stimulation of the somatotropic axis. This guide details supplier quality criteria, structural mechanisms, handling protocols, and analytical verification methods for laboratory researchers looking to buy CJC-1295.
To buy CJC-1295 for qualified in vitro or animal research, principal investigators must source from dedicated USA-manufactured suppliers providing lot-specific third-party analytical verification. High-purity CJC-1295 must be accompanied by Reverse-Phase High-Performance Liquid Chromatography (RP-HPLC) and Mass Spectrometry (MS) documentation confirming purity exceeding 98%, along with quantitative endotoxin testing for cellular assay safety.
Navigating the procurement of research peptides requires strict adherence to institutional standards. Sourcing CJC-1295 demands clear analytical transparency, cold-chain integrity during transport, and absolute batch traceability. PX1 Research provides certified reference-grade materials specifically synthesized for non-clinical research applications, shipping directly from facilities in California and Arizona.
CJC-1295 is a 29-amino acid tetrasubstituted peptide analog of endogenous Growth Hormone-Releasing Hormone (GHRH 1-29). Endogenous GHRH undergoes rapid enzymatic cleavage in vivo, primarily via dipeptidyl peptidase IV (DPP-IV), resulting in a short biological half-life of less than 12 minutes. CJC-1295 incorporates structural substitutions—specifically D-alanine at position 2, glutamine at position 8, alanine at position 15, and leucine at position 27—to enhance enzymatic stability while retaining affinity for the GHRH receptor (GHRH-R).
Preclinical studies suggest that binding of CJC-1295 to GHRH-R on anterior pituitary somatotrophs activates the adenylate cyclase/cAMP signaling cascade. This intracellular signaling triggers the transcription and pulsatile release of endogenous growth hormone (GH). Downstream of pituitary GH secretion, hepatic transcription of insulin-like growth factor 1 (IGF-1) is upregulated. In vitro assays demonstrate that this continuous or amplified activation of the somatotropic axis supports various cellular pathways involved in protein synthesis, cellular proliferation, and extracellular matrix remodeling.
When evaluating options to buy CJC-1295, researchers typically select between two distinct chemical modifications: CJC-1295 with Drug Affinity Complex (DAC) and CJC-1295 without DAC (frequently designated as Modified GRF 1-29). Understanding the pharmacokinetic differences between these variants is critical for experimental design.
The DAC modification consists of a maleimidopropionic acid linker covalently attached to the lysine residue at the C-terminus. In animal models, this reactive moiety selectively binds to free circulating albumin upon administration, forming a bioconjugate that protects the peptide from renal clearance and proteolysis. This extends the biological half-life significantly, supporting sustained GHRH-R activation over several days. Conversely, CJC-1295 No DAC lacks this linker, presenting a half-life measured in minutes to hours. This shorter duration closely mimics natural physiological GHRH pulses, making it ideal for studies investigating acute somatotropic responses.
In animal models, CJC-1295 has been extensively investigated for its downstream physiological effects following sustained GH and IGF-1 elevation. Researchers examine these hormonal shifts to understand tissue repair kinetics, skeletal muscle regeneration, and cellular turnover under conditions of stress or injury.
Rodent studies demonstrate that sustained elevation of circulating IGF-1 through GHRH agonist administration enhances nitrogen retention and promotes collagen deposition in damaged connective tissues. In vitro data indicate that activating GHRH-R pathways in fibroblast and satellite cell cultures upregulates cellular migration and proliferation. Consequently, investigators studying musculoskeletal healing often evaluate CJC-1295 DAC in combination with target-specific repair peptides such as BPC-157 to assess potential synergistic repair mechanisms.
To contextualize CJC-1295 within the broader landscape of somatotropic research compounds, investigators often perform comparative evaluations against other GHRH analogs and Growth Hormone Secretagogue Receptor (GHSR) agonists. Selecting the appropriate compound depends on whether the protocol demands receptor-specific activation, baseline pulsatility preservation, or maximum systemic exposure.
While CJC-1295 targets the GHRH receptor, ghrelin receptor agonists like Ipamorelin operate via an entirely distinct pathway, binding to GHSR-1a to trigger GH release without altering GHRH-R affinity. Older GHRH peptides such as Sermorelin retain the unmodified native sequence of GHRH 1-29, resulting in rapid hepatic clearance, whereas Tesamorelin features a hexenoyl moiety designed specifically for specialized lipolysis models. Researchers can explore PX1's full catalog of research peptides to compare molecular weights, binding affinities, and experimental parameters across these classes.
Maintaining structural integrity during receipt, storage, and reconstitution is essential for reproducible research outcome data. CJC-1295 is supplied as a lyophilized (freeze-dried) powder in sealed glass vials under vacuum or inert gas headspaces to prevent oxidative degradation.
Upon arrival at the laboratory, lyophilized CJC-1295 should be stored in a freezer at -20°C for short-term projects or -80°C for long-term storage, protected from light exposure. When preparing samples for in vitro assays or preclinical models, reconstitution should be performed using sterile bacteriostatic water or laboratory-grade normal saline. Gentle swirl agitation should be used to dissolve the cake; vigorous vortexing must be avoided as shear forces can denature delicate secondary peptide structures. Once reconstituted, liquid aliquots should be refrigerated at 2°C to 8°C and used within an established experimental window to prevent hydrolysis.
Due to variations in peptide synthesis standards across global supply chains, verifying chemical purity prior to study initiation is a critical prerequisite. Low-purity peptide batches or those contaminated with synthesis byproducts (such as truncated sequences or TFA salts) can alter cell culture viability and skew binding assay results.
A reliable source must provide a lot-specific Certificate of Analysis (COA) containing two mandatory analytical datasets: Reverse-Phase High-Performance Liquid Chromatography (RP-HPLC) to measure chemical purity percentage, and Electrospray Ionization Mass Spectrometry (ESI-MS) to verify precise molecular weight. Furthermore, for cellular and animal studies, quantitative Chromogenic LAL testing is required to verify that bacterial endotoxin levels remain well below published safety thresholds (<0.01 EU/μg). Research teams can review analytical methodology in the PX1 Research Library.
PX1 Research manufactures peptides in state-of-the-art facilities compliant with Good Manufacturing Practice (GMP) standards. By operating within domestic US facilities, chemical synthesis, purification, lyophilization, and quality control processing adhere to rigorous regulatory frameworks.
Domestic manufacturing eliminates the risks associated with international customs delays, temperature spikes during international transit, and untraceable overseas re-packagers. Institutional buyers accessing our lab account portal receive full batch documentation, guaranteeing lot-to-lot consistency across multi-phase longitudinal experiments.
What is the primary mechanism of CJC-1295 in preclinical research?
CJC-1295 acts as a synthetic GHRH receptor agonist. In preclinical models, it binds to GHRH receptors on anterior pituitary cells, stimulating the synthesis and pulsatile release of endogenous growth hormone (GH), which subsequently elevates circulating insulin-like growth factor 1 (IGF-1) levels.
What is the structural difference between CJC-1295 DAC and CJC-1295 No DAC?
CJC-1295 DAC incorporates a Drug Affinity Complex (maleimidopropionic acid) that covalently binds to circulating serum albumin, extending its biological half-life to several days in animal models. CJC-1295 No DAC lacks this linker, resulting in a short half-life measured in minutes to hours.
How should CJC-1295 be stored upon receipt in the laboratory?
Lyophilized CJC-1295 should be stored at -20°C or -80°C in a dry environment protected from light. After reconstitution with sterile laboratory diluent, liquid solutions should be kept refrigerated at 2°C to 8°C and used within designated experimental timelines.
What analytical tests verify the purity of CJC-1295?
Purity is verified via Reverse-Phase High-Performance Liquid Chromatography (RP-HPLC) to confirm peptide purity ≥98%, and Mass Spectrometry (MS) to confirm correct molecular weight. Endotoxin assays (LAL test) ensure the sample is suitable for delicate biological assays.
Is CJC-1295 approved for human consumption or therapeutic use?
No. CJC-1295 is strictly sold as a research compound for laboratory, in vitro, and preclinical research use only. It is not approved for human consumption, therapeutic treatment, or clinical diagnostic procedures.
How does PX1 Research guarantee lot consistency when buying CJC-1295?
Every batch of CJC-1295 synthesized by PX1 Research undergoes independent third-party testing at ISO 17025 accredited laboratories. Lot-specific COAs detailing HPLC, MS, and endotoxin data are published directly for research verification.
What diluent is recommended for reconstituting CJC-1295 for lab assays?
Sterile bacteriostatic water (0.9% benzyl alcohol) or sterile 0.9% sodium chloride solution is standard for laboratory reconstitution, depending on the specific requirements of the downstream in vitro or animal assay.
What shipping protocols are used to preserve peptide stability during transit?
PX1 Research ships orders same-day Monday through Friday from facilities in California and Arizona using protective packaging designed to prevent thermal exposure and physical degradation during transit.
All products are sold strictly for laboratory and research use only. Not for human or veterinary use, diagnosis, treatment or consumption. Statements have not been evaluated by the FDA.